KMT2A and acute myeloid leukemia: Acute myeloid leukemia (AML)-inducing oncoproteins, such as PML/RARα (promyelocytic leukemia/retinoic acid receptor alpha), PLZF/RARα (promyelocytic leukemia zinc finger/retinoic acid receptor alpha), MLL/AF9 (mixed lineage leukemia/AF9), CBFβ/SMMHC (core binding factor beta/smooth-muscle myosin heavy-chain), and RUNX1/ETO (runt-related transcription factor 1/eight-twenty-one), encoded by the disease-defining translocations t(15;17), t(11;17), t(9;11), inv(16) and t(8;21), respectively, follow common themes in the processes underlying the induction of AML [1].